Jayson Bedford
Stock Analyst at Raymond James
(3.97)
# 617
Out of 4,667 analysts
295
Total ratings
57.32%
Success rate
8.34%
Average return
Main Sectors:
Stocks Rated by Jayson Bedford
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MASI Masimo | Upgrades: Outperform | $170 | $164.95 | +3.06% | 5 | Nov 6, 2024 | |
| DXCM DexCom | Maintains: Strong Buy | $115 → $99 | $74.51 | +32.88% | 30 | Oct 25, 2024 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $128 → $123 | $109.27 | +12.57% | 6 | Oct 14, 2024 | |
| ISRG Intuitive Surgical | Maintains: Outperform | $500 → $540 | $541.82 | -0.34% | 7 | Oct 14, 2024 | |
| PODD Insulet | Maintains: Outperform | $213 → $260 | $266.58 | -2.47% | 25 | Oct 14, 2024 | |
| ABT Abbott Laboratories | Maintains: Outperform | $122 → $129 | $115.93 | +11.27% | 27 | Oct 14, 2024 | |
| ICUI ICU Medical | Maintains: Outperform | $158 → $190 | $167.84 | +13.20% | 19 | Sep 12, 2024 | |
| BSX Boston Scientific | Maintains: Strong Buy | $91 → $94 | $90.49 | +3.88% | 22 | Sep 4, 2024 | |
| BDX Becton, Dickinson and Company | Maintains: Outperform | $275 → $270 | $221.29 | +22.01% | 3 | Aug 2, 2024 | |
| AXGN Axogen | Initiates: Outperform | $13 | $12.90 | +0.78% | 1 | Jul 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $89 | $104.08 | -14.49% | 25 | Jan 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $10 | $6.74 | +48.37% | 14 | Jan 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $172 → $175 | $153.37 | +14.10% | 20 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $227 → $271 | $188.18 | +44.01% | 12 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $9.83 | - | 10 | Nov 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $30.15 | - | 13 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $69.80 | - | 20 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $32.33 | - | 6 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $84.20 | - | 14 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $0.31 | - | 4 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $86 | $78.04 | +10.20% | 4 | Nov 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.48 | - | 5 | Aug 2, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $22.93 | - | 3 | Jan 2, 2018 |
Masimo
Nov 6, 2024
Upgrades: Outperform
Price Target: $170
Current: $164.95
Upside: +3.06%
DexCom
Oct 25, 2024
Maintains: Strong Buy
Price Target: $115 → $99
Current: $74.51
Upside: +32.88%
Zimmer Biomet Holdings
Oct 14, 2024
Maintains: Outperform
Price Target: $128 → $123
Current: $109.27
Upside: +12.57%
Intuitive Surgical
Oct 14, 2024
Maintains: Outperform
Price Target: $500 → $540
Current: $541.82
Upside: -0.34%
Insulet
Oct 14, 2024
Maintains: Outperform
Price Target: $213 → $260
Current: $266.58
Upside: -2.47%
Abbott Laboratories
Oct 14, 2024
Maintains: Outperform
Price Target: $122 → $129
Current: $115.93
Upside: +11.27%
ICU Medical
Sep 12, 2024
Maintains: Outperform
Price Target: $158 → $190
Current: $167.84
Upside: +13.20%
Boston Scientific
Sep 4, 2024
Maintains: Strong Buy
Price Target: $91 → $94
Current: $90.49
Upside: +3.88%
Becton, Dickinson and Company
Aug 2, 2024
Maintains: Outperform
Price Target: $275 → $270
Current: $221.29
Upside: +22.01%
Axogen
Jul 1, 2024
Initiates: Outperform
Price Target: $13
Current: $12.90
Upside: +0.78%
Jan 30, 2024
Maintains: Outperform
Price Target: $84 → $89
Current: $104.08
Upside: -14.49%
Jan 9, 2024
Maintains: Outperform
Price Target: $12 → $10
Current: $6.74
Upside: +48.37%
Jan 3, 2024
Maintains: Outperform
Price Target: $172 → $175
Current: $153.37
Upside: +14.10%
Dec 20, 2023
Maintains: Outperform
Price Target: $227 → $271
Current: $188.18
Upside: +44.01%
Nov 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $9.83
Upside: -
Apr 24, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $30.15
Upside: -
Feb 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $69.80
Upside: -
Jan 5, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $32.33
Upside: -
Aug 24, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $84.20
Upside: -
Mar 5, 2021
Downgrades: Underperform
Price Target: n/a
Current: $0.31
Upside: -
Nov 5, 2020
Maintains: Outperform
Price Target: $75 → $86
Current: $78.04
Upside: +10.20%
Aug 2, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $2.48
Upside: -
Jan 2, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $22.93
Upside: -